Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial
Abstract Background Currently, the standard therapy for autoimmune hepatitis (AIH) consists of a combination of prednisolone and azathioprine. However, 15% of patients are intolerant to azathioprine which necessitates cessation of azathioprine or changes in therapy. In addition, not all patients ach...
Main Authors: | Romée J. A. L. M. Snijders, Anna E. C. Stoelinga, Tom J. G. Gevers, Simon Pape, Maaike Biewenga, Robert C. Verdonk, Hendrik J. M. de Jonge, Jan Maarten Vrolijk, Sjoerd F. Bakker, Thomas Vanwolleghem, Ynto S. de Boer, Martine A. M. C. Baven Pronk, Ulrich H. W. Beuers, Adriaan J. van der Meer, Nicole M. F. van Gerven, Marijn G. M. Sijtsma, Bart J. Verwer, Ingrid A. M. Gisbertz, Maartje Bartelink, Floris F. van den Brand, Kerem Sebib Korkmaz, Aad P. van den Berg, Maureen M. J. Guichelaar, Khalida Soufidi, Amar D. Levens, Bart van Hoek, Joost P. H. Drenth, on behalf of the Dutch Autoimmune Hepatitis Working Group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-022-06890-w |
Similar Items
-
Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial
by: Anna E. C. Stoelinga, et al.
Published: (2024-01-01) -
Matching adherence interventions to patient determinants using the Theoretical Domains Framework
by: Samuel Sebastian Allemann, et al.
Published: (2016-11-01) -
The effect of Patient’s Own Medication use on patient’s self-reported medication knowledge during hospitalisation: a pre-post intervention study
by: Loes J. M. van Herpen-Meeuwissen, et al.
Published: (2022-03-01) -
Supertuning your Z-28 Camaro/
by: 311372 Oldham, Joe
Published: (1981) -
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
by: Céleste J.T. van der Togt, et al.
Published: (2022-12-01)